129 related articles for article (PubMed ID: 38547766)
1. Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.
Staropoli N; Scionti F; Farenza V; Falcone F; Luciano F; Renne M; Di Martino MT; Ciliberto D; Tedesco L; Crispino A; Labanca C; Cucè M; Esposito S; Agapito G; Cannataro M; Tassone P; Tagliaferri P; Arbitrio M
Biomed Pharmacother; 2024 May; 174():116478. PubMed ID: 38547766
[TBL] [Abstract][Full Text] [Related]
2. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
Şendur MA; Aksoy S; Yorgun H; Ozdemir N; Yilmaz FM; Yazıcı O; Zungun C; Aytemir K; Zengin N; Altundag K
Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital.
Ayres LR; de Almeida Campos MS; de Oliveira Gozzo T; Martinez EZ; Ungari AQ; de Andrade JM; Pereira LR
Int J Clin Pharm; 2015 Apr; 37(2):365-72. PubMed ID: 25637407
[TBL] [Abstract][Full Text] [Related]
6. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.
Stanton SE; Ward MM; Christos P; Sanford R; Lam C; Cobham MV; Donovan D; Scheff RJ; Cigler T; Moore A; Vahdat LT; Lane ME; Chuang E
BMC Cancer; 2015 Apr; 15():267. PubMed ID: 25885598
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.
Yu AF; Yadav NU; Lung BY; Eaton AA; Thaler HT; Hudis CA; Dang CT; Steingart RM
Breast Cancer Res Treat; 2015 Jan; 149(2):489-95. PubMed ID: 25552363
[TBL] [Abstract][Full Text] [Related]
9. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
10. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
[TBL] [Abstract][Full Text] [Related]
12. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
Yu AF; Flynn JR; Moskowitz CS; Scott JM; Oeffinger KC; Dang CT; Liu JE; Jones LW; Steingart RM
JAMA Cardiol; 2020 Mar; 5(3):309-317. PubMed ID: 31939997
[TBL] [Abstract][Full Text] [Related]
13. Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study.
Feng Y; Qin Z; Yang Z
J Clin Pharm Ther; 2021 Feb; 46(1):93-98. PubMed ID: 32975332
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
[TBL] [Abstract][Full Text] [Related]
15. Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab.
Andersson AE; Linderholm B; Giglio D
Acta Oncol; 2021 Apr; 60(4):475-481. PubMed ID: 33191817
[TBL] [Abstract][Full Text] [Related]
16. Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer.
Choe JC; Choi JH; Choi JH; Ahn J; Park JS; Lee HW; Oh JH; Lee HC; Cha KS; Hong TJ
Clin Cardiol; 2018 Oct; 41(10):1308-1314. PubMed ID: 30239009
[TBL] [Abstract][Full Text] [Related]
17. Conventional cardiac risk factors associated with trastuzumab-induced cardiotoxicity in breast cancer: Systematic review and meta-analysis.
Koulaouzidis G; Yung AE; Yung DE; Skonieczna-Żydecka K; Marlicz W; Koulaouzidis A; Charisopoulou D
Curr Probl Cancer; 2021 Oct; 45(5):100723. PubMed ID: 33726923
[TBL] [Abstract][Full Text] [Related]
18. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
[TBL] [Abstract][Full Text] [Related]
19. Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients.
Marinko T; Stojanov Konda JT; Dolžan V; Goričar K
Dis Markers; 2020; 2020():6645588. PubMed ID: 33425072
[TBL] [Abstract][Full Text] [Related]
20. Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity.
Bergamini C; Dolci G; Rossi A; Torelli F; Ghiselli L; Trevisani L; Vinco G; Truong S; La Russa F; Golia G; Molino A; Benfari G; Ribichini FL
Clin Cardiol; 2018 Mar; 41(3):349-353. PubMed ID: 29569424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
